These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 20078490)

  • 1. Problems experienced by community pharmacists delivering opioid substitution treatment in New South Wales and Victoria, Australia.
    Winstock AR; Lea T; Sheridan J
    Addiction; 2010 Feb; 105(2):335-42. PubMed ID: 20078490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dispensing opioid substitution treatment: practices, attitudes and intentions of community-based pharmacists.
    Lawrinson P; Roche A; Terao H; Le PP
    Drug Alcohol Rev; 2008 Jan; 27(1):47-53. PubMed ID: 18034381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of diversion and injection of methadone and buprenorphine among clients receiving opioid treatment at community pharmacies in New South Wales, Australia.
    Winstock AR; Lea T; Sheridan J
    Int J Drug Policy; 2008 Dec; 19(6):450-8. PubMed ID: 18359216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. What is diversion of supervised buprenorphine and how common is it?
    Winstock AR; Lea T; Sheridan J
    J Addict Dis; 2009 Jul; 28(3):269-78. PubMed ID: 20155596
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of community pharmacy dispensing fees on the introduction of buprenorphine - naloxone in Australia.
    Winstock AR; Lea T; Ritter A
    Drug Alcohol Rev; 2007 Jul; 26(4):411-6. PubMed ID: 17564877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Buprenorphine supply by community pharmacists in Victoria, Australia: perceptions, experiences and key issues identified.
    Nielsen S; Dietze P; Dunlop A; Muhleisen P; Lee N; Taylor D
    Drug Alcohol Rev; 2007 Mar; 26(2):143-51. PubMed ID: 17364849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patients' help-seeking behaviours for health problems associated with methadone and buprenorphine treatment.
    Winstock AR; Lea T; Sheridan J
    Drug Alcohol Rev; 2008 Jul; 27(4):393-7. PubMed ID: 18584389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Community pharmacies and the provision of opioid substitution services for drug misusers: changes in activity and attitudes of community pharmacists across England 1995-2005.
    Sheridan J; Manning V; Ridge G; Mayet S; Strang J
    Addiction; 2007 Nov; 102(11):1824-30. PubMed ID: 17935587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Factors influencing pharmacy services in opioid substitution treatment.
    Chaar BB; Wang H; Day CA; Hanrahan JR; Winstock AR; Fois R
    Drug Alcohol Rev; 2013 Jul; 32(4):426-34. PubMed ID: 23442133
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV prevention and drug treatment services for drug misusers: a national study of community pharmacists' attitudes and their involvement in service specific training.
    Sheridan J; Strang J; Taylor C; Barber N
    Addiction; 1997 Dec; 92(12):1737-48. PubMed ID: 9581006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients.
    Larance B; Degenhardt L; O'Brien S; Lintzeris N; Winstock A; Mattick RP; Bell J; Ali R
    Drug Alcohol Rev; 2011 Nov; 30(6):613-20. PubMed ID: 21355939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacists' views on Indigenous health: is there more that can be done?
    Stoneman J; Taylor SJ
    Rural Remote Health; 2007; 7(3):743. PubMed ID: 17688377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.
    Burns L; Gisev N; Larney S; Dobbins T; Gibson A; Kimber J; Larance B; Mattick RP; Butler T; Degenhardt L
    Addiction; 2015 Apr; 110(4):646-55. PubMed ID: 25516077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacists' perceptions of their role in asthma management and barriers to the provision of asthma services.
    Kritikos VS; Reddel HK; Bosnic-Anticevich SZ
    Int J Pharm Pract; 2010 Aug; 18(4):209-16. PubMed ID: 20636672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First insights into community pharmacy based buprenorphine-naloxone dispensing in Finland.
    Uosukainen H; Bell JS; Laitinen K; Tacke U; Ilomäki J; Turunen JH
    Int J Drug Policy; 2013 Sep; 24(5):492-7. PubMed ID: 23567099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Satisfaction guaranteed? What clients on methadone and buprenorphine think about their treatment.
    Madden A; Lea T; Bath N; Winstock AR
    Drug Alcohol Rev; 2008 Nov; 27(6):671-8. PubMed ID: 19378450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diversion and injection of methadone and buprenorphine among clients in public opioid treatment clinics in New South Wales, Australia.
    Winstock AR; Lea T
    Subst Use Misuse; 2010; 45(1-2):240-52. PubMed ID: 20025451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of online training for the provision of opioid substitution treatment by community pharmacists in New Zealand.
    Walters C; Raymont A; Galea S; Wheeler A
    Drug Alcohol Rev; 2012 Nov; 31(7):903-10. PubMed ID: 22519647
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Consumer satisfaction with opioid treatment services at community pharmacies in Australia.
    Lea T; Sheridan J; Winstock A
    Pharm World Sci; 2008 Dec; 30(6):940-6. PubMed ID: 18850299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Substitution treatment for opiate dependence: survey of community pharmacies in Aquitaine].
    Jeantaud I; Haramburu F; Bégaud B
    Therapie; 1999; 54(2):251-5. PubMed ID: 10394262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.